<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580306</url>
  </required_header>
  <id_info>
    <org_study_id>1220.58</org_study_id>
    <secondary_id>2011-005442-35</secondary_id>
    <nct_id>NCT01580306</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to investigate the influence of mild, moderate and severe
      renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control
      group with normal renal function after single dose of BI 201335.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00,16:00, 24:00, 36:00, 48:00, 72:00, 96:00, 120:00, 144:00 hours (h) after administration</time_frame>
    <description>area under the concentration time curve of Faldaprevir in plasma over the time interval from 0 to infinity.
In this endpoint, the data of AUC0-∞ show inter-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00,16:00, 24:00, 36:00, 48:00, 72:00, 96:00, 120:00, 144:00h after administration</time_frame>
    <description>maximum concentration of Faldaprevir in plasma. In this endpoint, the data of Cmax show inter-individual variabilities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG</measure>
    <time_frame>from drug administration up to 2 weeks</time_frame>
    <description>Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Related Adverse Events</measure>
    <time_frame>drug administration until end-of-study examination (7 to 14 days after drug administration)</time_frame>
    <description>number of participants with investigator-defined drug related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>BI 201335 relevant treatment dose (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 201335 relevant treatment dose (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>Relevant treatment dose capsule (A) for oral administration</description>
    <arm_group_label>BI 201335 relevant treatment dose (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>Relevant treatment dose capsule (B) for oral administration</description>
    <arm_group_label>BI 201335 relevant treatment dose (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Male and female healthy subjects with normal renal function and subjects with impaired
        renal function in relatively good health

        Exclusion criteria:

        Any relevant deviation from healthy conditions for healthy volunteers or significant
        diseases other than renal impairment for the renal impaired subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.58.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>July 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2015</results_first_posted>
  <last_update_submitted>July 3, 2015</last_update_submitted>
  <last_update_submitted_qc>July 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Renal Function</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
        </group>
        <group group_id="P2">
          <title>Mild Renal Impairment</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
        </group>
        <group group_id="P3">
          <title>Moderate Renal Impairment</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
        </group>
        <group group_id="P4">
          <title>Severe Renal Impairment</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Renal Function</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
        </group>
        <group group_id="B2">
          <title>Mild Renal Impairment</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
        </group>
        <group group_id="B3">
          <title>Moderate Renal Impairment</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
        </group>
        <group group_id="B4">
          <title>Severe Renal Impairment</title>
          <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="2.1"/>
                    <measurement group_id="B2" value="58.8" spread="9.3"/>
                    <measurement group_id="B3" value="67.1" spread="7.5"/>
                    <measurement group_id="B4" value="57.6" spread="9.5"/>
                    <measurement group_id="B5" value="61.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞</title>
        <description>area under the concentration time curve of Faldaprevir in plasma over the time interval from 0 to infinity.
In this endpoint, the data of AUC0-∞ show inter-individual variabilities.</description>
        <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00,16:00, 24:00, 36:00, 48:00, 72:00, 96:00, 120:00, 144:00 hours (h) after administration</time_frame>
        <population>Pharmacokinetic (PK) set: This subject set included all subjects in the treated set who provided at least 1 observation for at least 1 primary PK endpoint without important protocol violations relevant to the evaluation of PK, and who did not vomit at or before 2 times median tmax of unmetabolised faldaprevir.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>area under the concentration time curve of Faldaprevir in plasma over the time interval from 0 to infinity.
In this endpoint, the data of AUC0-∞ show inter-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: This subject set included all subjects in the treated set who provided at least 1 observation for at least 1 primary PK endpoint without important protocol violations relevant to the evaluation of PK, and who did not vomit at or before 2 times median tmax of unmetabolised faldaprevir.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76500" spread="95.7"/>
                    <measurement group_id="O2" value="86900" spread="89.8"/>
                    <measurement group_id="O3" value="136000" spread="67.2"/>
                    <measurement group_id="O4" value="129000" spread="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison mild : normal</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>113.57</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>93.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.58</ci_lower_limit>
            <ci_upper_limit>310.17</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison moderate : normal</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>178.31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>78.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.23</ci_lower_limit>
            <ci_upper_limit>373.03</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison severe : normal</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>169.21</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>97.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.19</ci_lower_limit>
            <ci_upper_limit>391.17</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>maximum concentration of Faldaprevir in plasma. In this endpoint, the data of Cmax show inter-individual variabilities.</description>
        <time_frame>0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00,16:00, 24:00, 36:00, 48:00, 72:00, 96:00, 120:00, 144:00h after administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum concentration of Faldaprevir in plasma. In this endpoint, the data of Cmax show inter-individual variabilities.</description>
          <population>PK set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3810" spread="80.7"/>
                    <measurement group_id="O2" value="4080" spread="144.0"/>
                    <measurement group_id="O3" value="6680" spread="63.2"/>
                    <measurement group_id="O4" value="4600" spread="135.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison mild : normal</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>107.22</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>107.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.16</ci_lower_limit>
            <ci_upper_limit>327.01</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison moderate : normal</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>175.52</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>70.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.55</ci_lower_limit>
            <ci_upper_limit>344.06</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>relative bioavailability comparison severe : normal</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>investigation of relative bioavailability (no formal testing)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>120.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>115</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.257</ci_lower_limit>
            <ci_upper_limit>309.736</ci_upper_limit>
            <estimate_desc>the standard deviation is actually the geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
        <description>Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>from drug administration up to 2 weeks</time_frame>
        <population>treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
          <description>Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>blood pressure systolic increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Drug Related Adverse Events</title>
        <description>number of participants with investigator-defined drug related adverse events.</description>
        <time_frame>drug administration until end-of-study examination (7 to 14 days after drug administration)</time_frame>
        <population>treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Capsule for oral administration (120 mg Faldaprevir)
subjects with estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Related Adverse Events</title>
          <description>number of participants with investigator-defined drug related adverse events.</description>
          <population>treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time the subject signed the informed consent (21 days before drug administration) through the observational phase to the end of study visit (7 to 14 days after dosing)</time_frame>
      <desc>Subjects were required to report spontaneously any adverse events (AEs) as well as the time of onset, duration and intensity of these events. In addition, each volunteer was assessed regularly by the medical staff throughout the clinical trial as well as at the end of observation and whenever necessary as deemed by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>BI 201335 Relevant Treatment Dose (Normal Renal Function)</title>
          <description>Capsule for oral administration
estimated glomerular filtration rate &gt;= 90 mL/min/1.73m2</description>
        </group>
        <group group_id="E2">
          <title>BI 201335 Relevant Treatment Dose (Mild Renal Impairment)</title>
          <description>Capsule for oral administration
estimated glomerular filtration rate 60-89 mL/min/1.73m2</description>
        </group>
        <group group_id="E3">
          <title>BI 201335 Relevant Treatment Dose (Moderate Renal Impairment)</title>
          <description>Capsule for oral administration
estimated glomerular filtration rate 30-59 mL/min/1.73m2</description>
        </group>
        <group group_id="E4">
          <title>BI 201335 Relevant Treatment Dose (Severe Renal Impairment)</title>
          <description>Capsule for oral administration
estimated glomerular filtration rate 15-29 mL/min/1.73m2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

